Form 4: TG Therapeutics Director Sells Shares for Tax Obligations

TG Therapeutics Director Yann Echelard sold 5,000 shares of common stock at $32.57 per share to cover income tax obligations, retaining 223,816 shares.

Summary

• Yann Echelard, a Director of TG THERAPEUTICS, INC. (TGTX), reported a transaction on November 24, 2025.
• He sold 5,000 shares of Common Stock at a price of $32.57 per share.
• The sale was conducted by the Company's restricted stock administrator to satisfy Mr. Echelard's income tax obligations.
• Following this transaction, Mr. Echelard beneficially owns 223,816 shares of Common Stock directly.
• The remaining beneficially owned shares include restricted Common Stock that vests over various time periods.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations, which is generally considered neutral in terms of market sentiment and does not reflect a change in the director's confidence in the company.

Future Outlook

This filing is a report of a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact, as the sale was for tax purposes and not indicative of a change in company fundamentals or a discretionary decision to reduce exposure.

Key Dates

Recommendation

The sale of 5,000 shares by Director Yann Echelard was explicitly stated to satisfy income tax obligations, not a discretionary sale based on a change in outlook for the company. This transaction is a routine event for executives and directors and does not indicate a shift in the company's fundamentals or future prospects, thus a 'hold' recommendation is appropriate as it provides no new information to alter an investment thesis.

Keywords

TG Therapeutics, TGTX, Yann Echelard, Form 4, insider trading, stock sale, director, beneficial ownership, tax obligations